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Abstract:
The effectiveness of hematopoietic stem cell transplantation (HSCT) for
mucopolysaccharidosis type II (MPS II, Hunter disease) remains controversial although recent
studies have shown HSCT provides more clinical impact. This study aims to evaluate the long-term
effectiveness of HSCT using the activity of daily living (ADL) scores in patients with MPS II. Sixty-nine
severely affected MPS II patients (19 patients who received HSCT and 50 untreated patients) and
40 attenuated affected patients (five with HSCT and 35 untreated) were investigated by a simplified
ADL questionnaire. The frequency of clinical findings and the scores of ADL (verbal, gross motor,
and the level of care) were analyzed statistically. The mean age of onset of 19 severely affected
patients who received HSCT was 1.40 years ± 1.06, which is not statistically different from that
of 50 untreated patients (p = 0.11). Macroglossia, frequent airway infection, hepatosplenomegaly,
joint contracture, and sleep apnea were less frequent in the HSCT-treated group of severe MPS II
patients. The severe phenotype HSCT treated group reported a statistically significant higher score
of verbal function and gross motor function between the ages of 10 and 15 years and a higher level
of care score between 10 and 20 years. Patients with the attenuated phenotype showed high ADL
scores, and all of five HSCT treated patients reported a lower frequency of frequent airway infection,
coarse skin, umbilical/inguinal hernia, hepatosplenomegaly, heart valve disorders, and carpal tunnel.
In conclusion, HSCT is effective, resulting in improvements in clinical features and ADL in patients
with MPS II. HSCT should be re-reviewed as a therapeutic option for MPS II patients.
Keywords: mucopolysaccharidoses; hunter syndrome; activity of daily living; hematopoietic stem
cell transplantation

1. Introduction
Mucopolysaccharidosis (MPS II, Hunter disease, iduronate-2-sulfatase deficiency, OMIM #309900)
is a lysosomal storage disorder with X-linked recessive inheritance characterized by the systemic
manifestations such as short stature, multiple joint contractures, dysmorphic face, airway narrowing
and infection, heart valve disorders, hepatosplenomegaly, visual and hearing difficulties and neurologic
disabilities [1,2]. Accumulation of glycosaminoglycans (GAGs) such as dermatan sulfate (DS) and
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heparan sulfate (HS) in the body causes these progressive manifestations. Patients with the severe
phenotype show cognitive impairment and neurological deterioration that lead to the early death
before adulthood, whereas patients with the attenuated phenotype usually manifest progressive
cardiopulmonary insufficiency, hearing impairment, and gradual decrease of the activity of daily living
(ADL) in the adulthood. Hematopoietic stem cell transplantation (HSCT) had been widely performed
as a therapeutic approach for patients with MPS I (Hurler syndrome) since the 1980s [3,4]. However,
HSCT for patients with MPS II has been controversial, and the early studies suggest that HSCT is not
effective for MPS II [5,6]. Since enzyme replacement therapy (ERT) for MPS II has been introduced into
practice, clinical benefits of ERT including physical endurance, pulmonary function, range of joint
motion, hepatosplenomegaly, coarse hair and skin, as well as the reduction of urinary excretion of
GAGs have been reported [7,8]. Brain disorders, bone dysplasia, and valvular heart diseases remain
an unmet challenge by the current ERT approach. In a more recent study, Kubaski et al. [9]. In 2017
reported the effects of HSCT on 146 MPS II patients. The overall conclusion was that HSCT improved
ADL, the findings by brain magnetic resonance imaging (MRI), and GAGs levels. Other reports on MPS
II patients with HSCT have supported a positive impact on the ADL and growth especially if HSCT is
performed at an early stage [10–16]. While HSCT provides considerable risks such as graft-versus-host
diseases, infections, and higher mortality rate during the treatment, it also has unique advantages
compared with ERT: lower total costs, one-time treatment if successful, and the potential CNS effects if
treated at an early age [9,13,17–20]. In this study, we have investigated the effectiveness of HSCT for
patients with MPS II, using a simplified ADL questionnaire in Japan. Our finding further demonstrates
that HSCT improved clinical manifestations and ADL of the patients with the severe phenotype.
2. Materials and Methods
The investigators at Gifu University sent the first questionnaire to 8969 departments (Pediatrics,
Internal Medicine, Orthopedics, Rehabilitation, Ophthalmology) of hospitals with 200 beds or more and
asked whether these institutes had patients with MPS II. The recovery rate of the first questionnaire was
27.0%. One hundred forty-six patients with MPS II (99 patients with the severe phenotype, 47 patients
with the attenuated phenotype) had been reported to Gifu University. The second questionnaire was
sent to each institute who had MPS II patients(s). This questionnaire included demographic data, clinical
manifestations, therapeutic management, and ADL in these patients investigated further. Data on 109
of 146 (74.7%) patients with MPS II (69 patients with the severe phenotype and 40 patients with the
attenuated phenotype) were collected (Table 1) between the years of 2000 and 2007. All subjects were
Japanese. The questionnaires were filled out by the patient and family, based on the patient’s current
symptoms. ERT for MPS II patients was approved in Japan in 2006 [21]. Two untreated patients with
the attenuated phenotype reported receiving ERT. This does not impact our conclusion for HSCT. The
simplified ADL scoring table was developed as shown in Table 2. This table is a simplified version of
the validated FIM that has been used to evaluate ADL scores [22]. Verbal function, gross motor function,
and the level of care in each patient were evaluated based on this scoring system and defined in Table 2.
Rates and proportions were compared using the t-test or χ2 test. This study was approved by the
Institutional Review Board of Gifu University (approval code: 23-233, approval date: 1 January 2012).
3. Results
3.1. Patients’ Characteristics and Clinical Manifestations
Demographics of 109 patients with MPS II are summarized in Table 1. Sixty-nine and 40 patients
were categorized into the severe and the attenuated phenotypes based on the clinical severity and
the presence of cognitive impairment. Mean age at onset, age at diagnosis, and the age at this study
in the patients with the severe phenotype were significantly younger (p < 0.01) than those with the
attenuated phenotype. Nineteen out of 69 (27.5%) patients with the severe phenotype received HSCT.
Statistical differences between the age at onset, diagnosis, and at time of the study were not observed
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between HSCT-treated and untreated groups for both the severe and the attenuated phenotypes. Only 5
out of 40 (12.5%) patients with the attenuated phenotype received HSCT.
Table 1. Characteristics of patients with mucopolysaccharidosis (MPS II).

Number of patients (M/F)
Age at onset (year)
Age at diagnosis (year)
Age at study (year)

Severe Phenotype

Attenuated Phenotype

69 (68/1)
1.68 ± 1.30 **
3.2 ± 1.80 **
10.85 ± 5.86 **

40 (40/0)
3.08 ± 2.28
7.08 ± 5.75
16.69 ± 8.02

HSCT
Number of patients

+
19

−
50

+
5

−
35

Age at onset (year)
Age at diagnosis (year)
Age in this study (year)
Age at HSCT

1.40 ± 1.06
2.78 ± 1.77
10.89 ± 5.45
4.11 ± 2.42

1.87 ± 1.38
3.36 ± 1.80
10.84 ± 6.07

2.5 ± 2.18
3.4 ± 2.07
13.0 ± 8.28
5.0 ± 2.74

3.14 ± 2.27
7.64 ± 5.94
17.3 ± 7.95

Clinical findings (%)
Facial dysmorphism
Macroglossia
Frequent airway infection
Coarse skin/hypertrichosis
Umbilical/inguinal hernia
Hepatomegaly/splenomegaly
Joint contracture
Heart valve disorders
Corneal clouding
Hearing difficulty
Sleep apnea
Central nervous symptoms
Carpal tunnel syndrome
Dilated ventricle (MRI)

89
59 **
50 **
79
56
78 *
84 *
63
6
67
11 **
89
0
47

100
90
83
98
69
96
100
80
13
85
63
98
0
71

100
0 **
20 *
40 **
25 *
40 **
60
60 *
0
60
0
40
20 *
40

100
68
76
91
81
94
100
94
12
77
35
47
16
39

* p < 0.05 ** p < 0.01. Note; Mean and standard deviation reported for 109 of 146 patients with MPS II. Patients were
surveyed for the phenotype of MPS II, hematopoietic stem cell transplantation (HSCT) treatment, and physical
symptoms of MPS II.

In the untreated patients with either of the severe or attenuated phenotype, facial dysmorphism,
frequent airway infection, coarse skin/hypertrichosis, umbilical/inguinal hernia, hepatosplenomegaly,
joint contracture, heart valve disorders, and hearing difficulty were common clinical features.
Macroglossia, sleep apnea, and cognitive impairment were more frequently observed in patients with
the severe phenotype. Carpal tunnel syndrome and corneal clouding were observed in a smaller
percentage of the patients. In the HSCT-treated group with the severe phenotype, macroglossia, frequent
airway infection, hepatosplenomegaly, joint contracture, and sleep apnea were less frequently observed
when compared with the untreated patients. In the HSCT-treated group of the attenuated phenotype,
airway infection and coarse skin/hypertrichosis, umbilical/inguinal hernia, hepatosplenomegaly,
joint contracture, heart valve disorders, and carpal tunnel syndrome were less frequently observed.
3.2. Natural History of ADL of MPS II
Data from the questionnaires were used to score the ADL of patients based on a simplified ALD
scoring table (Table 2).
Table 2. Scoring table for activity of daily living (ADL) in patients with MPS II.
Category
Verbal function
Gross motor function
Level of care

4
Ordinary conversation
Ordinary walk
Independent

3
Two-words sentence
Walk with stick

2
Single-word
Walk with aid
Moderately dependent

1
Babbling
Wheelchair

0
No word
Bed-ridden
Highly dependent
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Scores of ADL in untreated patients with severe or attenuated phenotypes are graphed in Figure
1. Data from the untreated patients provide a natural course of ADL in MPS II patients. In untreated
patients
the severe
phenotype,
the mean
ADL score
of verbal phenotypes
function between
the agesinofFigure
five 1.
Scoreswith
of ADL
in untreated
patients
with severe
or attenuated
are graphed
and
nine
years
was
slightly
higher
than
that
of
ages
four
and
below,
but
it
decreased
rapidly
at
10
Data from the untreated patients provide a natural course of ADL in MPS II patients. In untreated
years of age (Figure 1A). The mean score of gross motor function was highest (ordinary walk) at four
patients with the severe phenotype, the mean ADL score of verbal function between the ages of five
years of age or younger, but gradually decreased as age progressed (Figure 1A). The mean score
and nine years was slightly higher than that of ages four and below, but it decreased rapidly at 10 years
indicated that the patients with the severe phenotype could walk with aid between five and 15 years;
of age (Figure 1A). The mean score of gross motor function was highest (ordinary walk) at four years
however, they became wheelchair-bound after 15 years of age, and then bed-ridden in adulthood
of age or younger, but gradually decreased as age progressed (Figure 1A). The mean score indicated
(Figure 1A). The level of care was highest between the ages of five and nine and decreased after nine
that
the patients with the severe phenotype could walk with aid between five and 15 years; however,
years of age (Figure 1A).
they became
wheelchair-bound
after 15 years
of age,verbal
and then
bed-ridden
in adulthood
In the patients
with the attenuated
phenotype,
function,
gross motor
function,(Figure
and the1A).
The
level
of
care
was
highest
between
the
ages
of
five
and
nine
and
decreased
after
nine
years
of age
level of care were maintained in normal up to 20 years of age; however, the score of gross motor
(Figure
1A).
function and the level of care slightly declined after 20 years of age (Figure 1B).

(A)

(B)
Figure 1. (A) ADL scores for untreated severe MPS II patients. (B) ADL scores of untreated attenuated
MPS II patients.
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In the patients with the attenuated phenotype, verbal function, gross motor function, and the level
Figure
1. (A)
ADL scores
untreated
severe
MPS of
II patients.
(B) ADL
scores
ofof
untreated
attenuated
of care
were
maintained
infor
normal
up to
20 years
age; however,
the
score
gross motor
function
MPS
II
patients.
and the level of care slightly declined after 20 years of age (Figure 1B).

3.3.
ADL
ofofPatients
3.3.
ADL
PatientsTreated
Treatedwith
withHSCT
HSCT
ADL
werecompared
compared
between
HSCT-treated
vs. untreated
patients
with
a severe
ADLscores
scores were
between
HSCT-treated
vs. untreated
patients with
a severe
phenotype
phenotype
2). There
were nodifferences
statistical in
differences
theonset,
ages at
onset, the
diagnosis,
and
(Figure 2).(Figure
There were
no statistical
the ages atinthe
thethe
diagnosis,
and
age at study
age
at study
the HSCT-treated
untreated
MPS
patients.above,
As described
above,
between
thebetween
HSCT-treated
vs. untreatedvs.
severe
MPS IIsevere
patients.
AsIIdescribed
macroglossia,
macroglossia,
frequent
airway
infection,
coarse skin, hepatosplenomegaly,
contracture,
and
frequent airway
infection,
coarse
skin, hepatosplenomegaly,
joint contracture, joint
and sleep
apnea were
less apnea
frequent
in patients
who received
HSCT
(Table
1). Sleep
apnea
was1).
significantly
less
often
observed
sleep
were
less frequent
in patients
who
received
HSCT
(Table
Sleep apnea
was
significantly
in often
the HSCT-treated
for the agespatients
betweenfor
10the
andages
15 years
(Figure
3). 15 years (Figure 3).
less
observed inpatients
the HSCT-treated
between
10 and

(A)

(B)
Figure 2. Cont.
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(C)
Figure
and
untreated
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**
Figure2.
2.(A)
(A)Verbal
Verbalfunction
function
ADL
scores
of
severe
phenotype
HSCT-treated
and
untreated
groups.
Figure
2.
functionADL
ADLscores
scoresof
ofsevere
severephenotype
phenotypeHSCT-treated
HSCT-treated
and
untreated
groups.
=*==
ppp<<<0.05.
(B)
Gross
motor
function
ADL
scores
of
severe
phenotype
HSCT-treated
and
untreated
0.05.
and untreated
untreated
0.05.(B)
(B)Gross
Grossmotor
motorfunction
functionADL
ADL scores
scores of
of severe phenotype HSCT-treated and
groups.
groups.** ==
=pp<<
<0.05.
0.05.
(C)
Level
of
Care
ADLscores
scoresof
ofsevere
anduntreated
untreated
groups.
0.05.(C)
(C)Level
Levelof
ofCare
CareADL
severe phenotype
phenotype HSCT-treated
HSCT-treated and
and
untreated
groups.
groups.** ==
=pp<<<0.05.
0.05.
groups.
0.05.

Figure 3. Sleep apnea in severe phenotype MPS-II patients. * = p < 0.05.
Figure
Figure3.3.Sleep
Sleepapnea
apneain
insevere
severephenotype
phenotypeMPS-II
MPS-IIpatients.
patients.**==pp<<0.05.
0.05.

As shown in Figure 2, ADL scores of HSCT-treated patients were generally better than those
As
As shown
shown in
in Figure
Figure 2,
2, ADL
ADL scores
scores of
of HSCT-treated
HSCT-treated patients
patients were
were generally
generally better
better than
than those
those
untreated patients. The score of verbal function was not different between both groups before 10 years of
untreated
untreated patients.
patients. The
The score
score of
of verbal
verbal function
function was
was not
not different
different between
between both
both groups
groups before
before 10
10
age but was significantly higher in the HSCT-treated group between 10 and 15 years of age (Figure 2A).
years
years of
ofage
age but
but was
wassignificantly
significantly higher
higherin
in the
the HSCT-treated
HSCT-treatedgroup
groupbetween
between10
10and
and15
15years
yearsof
of age
age
The score of gross motor function remained relatively high between five and 15 years of age. The ADL
(Figure
(Figure2A).
2A).The
Thescore
scoreof
ofgross
grossmotor
motorfunction
functionremained
remainedrelatively
relativelyhigh
highbetween
betweenfive
fiveand
and15
15years
yearsof
of
scores of the HSCT treated group was significantly higher in the HSCT-treated group compared to
age.
age.The
TheADL
ADLscores
scoresof
ofthe
theHSCT
HSCTtreated
treatedgroup
groupwas
wassignificantly
significantlyhigher
higherin
inthe
theHSCT-treated
HSCT-treatedgroup
group
the untreated group between 10 and 15 years of age (Figure 2B). The level of care was significantly
compared
compared to
to the
the untreated
untreated group
group between
between 10
10 and
and 15
15 years
years of
of age
age (Figure
(Figure 2B).
2B). The
The level
level of
of care
care was
was
better in the HSCT-treated group between 10 and 15 years old and between 16 and 20 years old.
significantly
better
in
the
HSCT-treated
group
between
10
and
15
years
old
and
between
16
and
significantly better in the HSCT-treated group between 10 and 15 years old and between 16 and 20
20
However, both groups became highly age-dependent after 15 years of age (Figure 2C). ADL scores in
years
years old.
old. However,
However, both
both groups
groups became
became highly
highly age-dependent
age-dependent after
after 15
15 years
years of
of age
age (Figure
(Figure 2C).
2C).
HSCT-treated patients at three years of age or younger (n = 9) were slightly better than that of patients
ADL
ADLscores
scoresin
inHSCT-treated
HSCT-treatedpatients
patientsat
atthree
threeyears
yearsof
ofage
ageor
oryounger
younger(n
(n==9)
9)were
wereslightly
slightlybetter
betterthan
than
that
thatof
ofpatients
patientswho
whowere
wereHSCT-treated
HSCT-treatedat
atfour
fouryears
yearsof
ofage
ageor
orolder
older(n
(n==9)
9)(Figure
(Figure4)
4)(p-value:
(p-value:verbal
verbal
0.28,
0.28,motor
motor0.11,
0.11,care
care0.5).
0.5).

Diagnostics 2020, 10, 46

Diagnostics 2020, 10, x FOR PEER REVIEW

7 of 12

7 of 12

who were HSCT-treated at four years of age or older (n = 9) (Figure 4) (p-value: verbal 0.28, motor 0.11,
Note; Results of ADL survey for MPS II patients for the categories verbal function, gross motor
care 0.5).
function, and level of care. Rates and proportions were compared using the t-test or χ2 test.

Figure4.4.Age
AgeatatHSCT
HSCTand
andADL
ADLscores
scoresfor
forsevere
severephenotype
phenotypeMPS
MPSIIIIpatients.
patients.
Figure

Note; Results of ADL survey for MPS II patients for the categories verbal function, gross motor
4. Discussion
function, and level of care. Rates and proportions were compared using the t-test or χ2 test.
In this study, we have demonstrated a better clinical outcome and ADL in a relatively large
4.
Discussion
number of HSCT-treated patients with the severe phenotype. Clinical effectiveness of HSCT for
patients
with
MPSwe
II have
remains
controversial
[9,13,17,18].
Peters et
al.ADL
indicated
that all large
the patients
In this
study,
demonstrated
a better
clinical outcome
and
in a relatively
number
with
the
severe
phenotype
who
received
HSCT
reported
deteriorated
intellectual
abilities
after
HSCT
of HSCT-treated patients with the severe phenotype. Clinical effectiveness of HSCT for patients
with
(North
American
Storage
Disease
Collaborative
Study
Group)
[23].
He
also
raised
a
question
of
MPS II remains controversial [9,13,17,18]. Peters et al. indicated that all the patients with the severe
ethical
concerns
on
the
decision-making
of
HSCT
for
MPS
II
with
the
attenuated
phenotype,
because
phenotype who received HSCT reported deteriorated intellectual abilities after HSCT (North American
of
life-threatening
risks of HSCT.
In Group)
contrast,
other
suggested
that selected
patients
Storage
Disease Collaborative
Study
[23].
Heinvestigations
also raised a question
of ethical
concerns
on the
without
serious
neurological
complications
could
be
candidates
for
HSCT
[24,25].
Guffon
al.
decision-making of HSCT for MPS II with the attenuated phenotype, because of life-threateningetrisks
reported
that
HSCT
was
effective
on
eight
MPS
II
patients
with
a
broad
clinical
range
and
nonof HSCT. In contrast, other investigations suggested that selected patients without serious neurological
neurological
[26]. Scarpa
al. [27]
reviewed
thatetHSCT
could provide
sufficient
enzyme
complicationssymptoms
could be candidates
foretHSCT
[24,25].
Guffon
al. reported
that HSCT
was effective
on
activity
to
slow
or
stop
the
progression
of
the
disease.
However,
controlled
clinical
studies
should
be
eight MPS II patients with a broad clinical range and non-neurological symptoms [26]. Scarpa et al. [27]
conducted.
A study
by Kubaski
al. [9] has
demonstrated
improves of
ADL
reviewed that
HSCTperformed
could provide
sufficientetenzyme
activity
to slow orthat
stopHSCT
the progression
the
scores,
MRI
findings,
cognitive
function,
and
reduction
of
blood
GAG
levels
in
severe
MPS
II
patients
disease. However, controlled clinical studies should be conducted. A study performed by Kubaski
[9–16,19,28].
was littlethat
improvement
in HSCT
MPScognitive
II patients.
However,
et al. [9] has There
demonstrated
HSCT improves
ADLtreated
scores,attenuated
MRI findings,
function,
and
there
were
some
improvements
in
the
patients’
MRI
findings,
which
could
suggest
that
HSCT
could
reduction of blood GAG levels in severe MPS II patients [9–16,19,28]. There was little improvement in
delay
symptoms
attenuated
phenotypes.
With some
these improvements
findings, Kubaski
etpatients’
al. has
HSCTneurological
treated attenuated
MPS in
II patients.
However,
there were
in the
suggested
that
HSCT
is
a
good
therapeutic
option
for
MPS
II,
but
notes
that
the
earlier
HSCT
is
MRI findings, which could suggest that HSCT could delay neurological symptoms in attenuated
performed,
better
thefindings,
outcomes.
Our findings
in this
study support
foris
the
findings
in these recent
phenotypes.the
With
these
Kubaski
et al. has
suggested
that HSCT
a good
therapeutic
option
studies.
for MPS II, but notes that the earlier HSCT is performed, the better the outcomes. Our findings in this
MPS
II is for
thethe
most
prevalent
type
of MPS
in Japan [29] and in East Asia [30–33], and a
study
support
findings
in these
recent
studies.
considerable
number
of
patients
with
MPS
II
have
received
HSCT
in China
and Japan
However,
MPS II is the most prevalent type of MPS in Japan [29] and
in East
Asia [30–33],
and[10].
a considerable
only
a
few
systemic
evaluations
on
the
effectiveness
of
HSCT
have
been
performed
up
to
datea few
[9–
number of patients with MPS II have received HSCT in China and Japan [10]. However, only
11,19].
In evaluations
this study, we
a retrospective
questionnaire-based
MPS
II patients
in
systemic
on conducted
the effectiveness
of HSCT have
been performedstudy
up to of
date
[9–11,19].
In this
Japan
and
collected
clinical
data
from
109
patients
with
MPS
II.
Differences
in
clinical
findings
and
study, we conducted a retrospective questionnaire-based study of MPS II patients in Japan and collected
the
leveldata
of ADL
definedwith
between
patients with
the severe
phenotype
theofattenuated
clinical
fromwere
109 patients
MPSthe
II. Differences
in clinical
findings
and theand
level
ADL were
phenotype,
and
between
the
HSCT-treated
and
untreated
patients.
Our
analyzed
data
defined between the patients with the severe phenotype and the attenuated phenotype, andindicated
between
better
clinical consequences
in symptoms
of macroglossia,
airway
infection,
the HSCT-treated
and untreated patients.
Our analyzed
data indicated frequent
better clinical
consequences
in
hepatosplenomegaly, joint contracture, and sleep apnea in severe phenotype HSCT-treated group.
ADL scores in verbal function, gross motor function, and level of care are also better in the severe
phenotype treated group. However, verbal function rapidly deteriorated from single-word level to
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symptoms of macroglossia, frequent airway infection, hepatosplenomegaly, joint contracture, and sleep
apnea in severe phenotype HSCT-treated group. ADL scores in verbal function, gross motor function,
and level of care are also better in the severe phenotype treated group. However, verbal function
rapidly deteriorated from single-word level to no-word level after nine years of age in the untreated
group, while such level is reasonably maintained in the HSCT-treated group. Gross motor function
is preserved in both groups between five and nine years of age and between 10 and 15 years of age,
but the untreated patients are wheelchair-bound or bed-ridden after 15 years of age, whereas the
treated patients reported a slightly better ADL score average. The level of care is also significantly
higher in the treated patients between 10 and 20 years of age.
These results indicate that HSCT for patients with MPS II is effective not only for the somatic
symptoms but also for some neurological symptoms. HSCT has several advantages when compared
with ERT. Transplanted stem cells could migrate into the central nervous system and differentiate to
glial cells [34] and may have a more favorable effect on cognitive function compared to ERT [9,10].
Those receiving HSCT do not have to worry about an antibody response to the infused enzyme,
which could occur in ERT patients [9]. Patients do not need a weekly 4–5 h infusion of the enzyme for the
lifetime. The total costs of HSCT will be less expensive if the patient is fully engrafted by the one-time
procedure. The one-time cost of HSCT in Japan ranges between USD 70,000 and 205,000 [3,9,17–20,35].
The annual cost of ERT for a 25 kg MPS II patient in Japan is USD 400,000 [9,13].
On the other hand, HSCT also has risks and concerns. Life-threatening graft-versus-host reactions
and infections may occur in HSCT [36]. Although, recent studies have reported increased survival
rates in MPS II, including a study by Wang et al. [10], which reported a 100% survival rate in a 10-year
follow-up of HSCT treated MPS II patients. Long-term admission to a hospital and separation in
a bio-clean room is stressful for both patients and families [37]. Furthermore, we have no definite
evidence at present that HSCT should have sufficient efficacy for the severe patients MPS II although
HSCT provides a better clinical outcome compared with conventional ERT [9,13–15]. Our present
results indicate the better prognosis of HSCT-treated patients. However, the patients have still limited
verbal and motor function as compared with the healthy age-matched children, and verbal and motor
function are highly dependent on ages.
Further research of MPS II patients who are under two years of age at the time of HSCT, since a
more clinical impact on the CNS of MPS I patients treated under two years old has been observed [9,11].
Investigation and establishment of strategies for the early diagnosis and early treatment for MPS II are
needed. Newborn screening for MPS is essential to promote early diagnosis [38–40]. New delivery
strategies of the enzymes into the central nervous system are also under developing [41–53].
In parallel with the development of therapeutic regimes like HSCT and ERT, a simple method for
the evaluation of clinical severity and therapeutic efficacy is demanded. We previously reported the
usefulness of the functional independence measure (FIM) questionnaire [22]. A clear difference in ADL
and psychomotor development between MPS II patients with the severe and attenuated phenotype
was defined. The FIM questionnaire can be used for various diseases with neurological involvement.
However, it requires the evaluation by the experts and is time-consuming. In this study, we attempted
to use a novel and simple scoring table to assess a critical sketch of ADL in an individual patient,
leading to the success of the establishment of clinical severity score and clinical efficacy post-HSCT.
This revised method can be used by physicians and caregivers repeatedly and easily, although it could
be difficult to assess a subtle change of function in each patient.
In conclusion, we have evaluated clinical symptoms and ADL in patients with MPS II and have
identified significant differences in symptoms and ADL between HSCT-treated and untreated patients
with the severe phenotype of MPS II. These data should provide further evidence for not only the
natural history of MPS II but also the efficacy of HSCT.
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5. Limitations of the Study
Current scientific knowledge gaps in this study are: (i) lack of objectivity of the data resulting
from the use of a self-reported questionnaire, (ii) lack of an objective evaluation method to cover the
whole symptoms, and (iii) a limited number of patients with MPS II. Longitudinal and objective data
should be included in future investigation.
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